594 related articles for article (PubMed ID: 24517996)
21. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza.
Sidwell RW; Smee DF
Expert Opin Investig Drugs; 2002 Jun; 11(6):859-69. PubMed ID: 12036429
[TBL] [Abstract][Full Text] [Related]
22. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
Mancuso CE; Gabay MP; Steinke LM; Vanosdol SJ
Ann Pharmacother; 2010; 44(7-8):1240-9. PubMed ID: 20516360
[TBL] [Abstract][Full Text] [Related]
23. In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice.
Paukner S; Kimber S; Cumper C; Rea-Davies T; Sueiro Ballesteros L; Kirkham C; Hargreaves A; Gelone SP; Richards C; Wicha WW
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791439
[TBL] [Abstract][Full Text] [Related]
24. Pneumococcal conjugate vaccine modulates macrophage-mediated innate immunity in pneumonia caused by Streptococcus pneumoniae following influenza.
Mimura K; Kimura S; Kajiwara C; Nakakubo S; Schaller MA; Ishii Y; Standiford TJ; Kunkel SL; Tateda K
Microbes Infect; 2020 Sep; 22(8):312-321. PubMed ID: 31958572
[TBL] [Abstract][Full Text] [Related]
25. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).
Yun NE; Linde NS; Zacks MA; Barr IG; Hurt AC; Smith JN; Dziuba N; Holbrook MR; Zhang L; Kilpatrick JM; Arnold CS; Paessler S
Virology; 2008 Apr; 374(1):198-209. PubMed ID: 18234269
[TBL] [Abstract][Full Text] [Related]
26. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.
Pascua PNQ; Mostafa HH; Marathe BM; Vogel P; Russell CJ; Webby RJ; Govorkova EA
Sci Rep; 2017 Aug; 7(1):7345. PubMed ID: 28779075
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
Barroso L; Treanor J; Gubareva L; Hayden FG
Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
[TBL] [Abstract][Full Text] [Related]
28. Immune response after a single intravenous peramivir administration in children with influenza.
Sato M; Hashimoto K; Kawasaki Y; Hosoya M
Antivir Ther; 2018; 23(5):435-441. PubMed ID: 29372885
[TBL] [Abstract][Full Text] [Related]
29. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.
Kohno S; Yen MY; Cheong HJ; Hirotsu N; Ishida T; Kadota J; Mizuguchi M; Kida H; Shimada J;
Antimicrob Agents Chemother; 2011 Nov; 55(11):5267-76. PubMed ID: 21825298
[TBL] [Abstract][Full Text] [Related]
30. Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice.
Skarnovich MA; Emelyanova AG; Petrova NV; Borshcheva AA; Gorbunov EA; Mazurkov OY; Skarnovich MO; Tarasov SA; Shishkina LN; Epstein OI
Antivir Ther; 2017; 22(4):345-351. PubMed ID: 27924780
[TBL] [Abstract][Full Text] [Related]
31. Peramivir and its use in H1N1 influenza.
Castillo R; Holland LE; Boltz DA
Drugs Today (Barc); 2010 Jun; 46(6):399-408. PubMed ID: 20571608
[TBL] [Abstract][Full Text] [Related]
32. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus.
Baz M; Carbonneau J; Rhéaume C; Cavanagh MH; Boivin G
Viruses; 2018 Nov; 10(11):. PubMed ID: 30400276
[TBL] [Abstract][Full Text] [Related]
33. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
Baz M; Abed Y; Boivin G
Antiviral Res; 2007 May; 74(2):159-62. PubMed ID: 17137644
[TBL] [Abstract][Full Text] [Related]
34. Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza.
Yoo JW; Choi SH; Huh JW; Lim CM; Koh Y; Hong SB
J Med Virol; 2015 Oct; 87(10):1649-55. PubMed ID: 25946636
[TBL] [Abstract][Full Text] [Related]
35. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
Abed Y; Baz M; Boivin G
Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
[TBL] [Abstract][Full Text] [Related]
36. Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice.
Hatayama K; Nosaka N; Yamada M; Yashiro M; Fujii Y; Tsukahara H; Liu K; Nishibori M; Matsukawa A; Morishima T
J Med Virol; 2019 Mar; 91(3):361-369. PubMed ID: 30281823
[TBL] [Abstract][Full Text] [Related]
37. Coinfection with Streptococcus pneumoniae negatively modulates the size and composition of the ongoing influenza-specific CD8⁺ T cell response.
Blevins LK; Wren JT; Holbrook BC; Hayward SL; Swords WE; Parks GD; Alexander-Miller MA
J Immunol; 2014 Nov; 193(10):5076-87. PubMed ID: 25311807
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
Govorkova EA; Marathe BM; Prevost A; Rehg JE; Webster RG
Antiviral Res; 2011 Aug; 91(2):81-8. PubMed ID: 21635924
[TBL] [Abstract][Full Text] [Related]
40. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
